BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 33377401)

  • 1. Can quantifying the extent of 'high grade' features help explain prognostic variability in anaplastic astrocytoma?
    Goacher E; Mathew R; Fayaye O; Chakrabarty A; Feltbower R; Loughrey C; Roberts P; Chumas P
    Br J Neurosurg; 2024 Apr; 38(2):314-321. PubMed ID: 33377401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI.
    Fujii Y; Muragaki Y; Maruyama T; Nitta M; Saito T; Ikuta S; Iseki H; Hongo K; Kawamata T
    J Neurosurg; 2018 Jul; 129(1):1-9. PubMed ID: 28885120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting.
    Jain S; Gupta P; Shankar KB; Singh R; Siraj F
    J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A molecular classification system for anaplastic glioma].
    Jiang HH; Ren XH; Zhang Z; Lin S
    Zhonghua Wai Ke Za Zhi; 2013 Dec; 51(12):1104-9. PubMed ID: 24499721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.
    Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C
    Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
    Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
    [No Abstract]   [Full Text] [Related]  

  • 8. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.
    Jiang H; Ren X; Cui X; Wang J; Jia W; Zhou Z; Lin S
    Neuro Oncol; 2013 Jun; 15(6):775-82. PubMed ID: 23486687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival, Prognostic Factors, and Volumetric Analysis of Extent of Resection for Anaplastic Gliomas.
    Hong JB; Roh TH; Kang SG; Kim SH; Moon JH; Kim EH; Ahn SS; Choi HJ; Cho J; Suh CO; Chang JH
    Cancer Res Treat; 2020 Oct; 52(4):1041-1049. PubMed ID: 32324987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of patients with WHO Grade III and IV gliomas treated by fractionated intracavitary radioimmunotherapy.
    Reulen HJ; Poepperl G; Goetz C; Gildehaus FJ; Schmidt M; Tatsch K; Pietsch T; Kraus T; Rachinger W
    J Neurosurg; 2015 Sep; 123(3):760-70. PubMed ID: 26140493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51.
    Daniels TB; Brown PD; Felten SJ; Wu W; Buckner JC; Arusell RM; Curran WJ; Abrams RA; Schiff D; Shaw EG
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):218-24. PubMed ID: 21549518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients.
    Chen N; Yu T; Gong J; Nie L; Chen X; Zhang M; Xu M; Tan J; Su Z; Zhong J; Zhou Q
    Pathology; 2016 Dec; 48(7):675-683. PubMed ID: 27780605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.
    Antonelli M; Buttarelli FR; Arcella A; Nobusawa S; Donofrio V; Oghaki H; Giangaspero F
    J Neurooncol; 2010 Sep; 99(2):209-15. PubMed ID: 20174854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.
    Zeng A; Hu Q; Liu Y; Wang Z; Cui X; Li R; Yan W; You Y
    Oncotarget; 2015 Oct; 6(30):30232-8. PubMed ID: 26338964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas.
    Tortosa A; Viñolas N; Villà S; Verger E; Gil JM; Brell M; Caral L; Pujol T; Acebes JJ; Ribalta T; Ferrer I; Graus F
    Cancer; 2003 Feb; 97(4):1063-71. PubMed ID: 12569607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
    Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
    J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort.
    Pollack IF; Hamilton RL; Burnham J; Holmes EJ; Finkelstein SD; Sposto R; Yates AJ; Boyett JM; Finlay JL
    Neurosurgery; 2002 Jun; 50(6):1238-44; discussion 1244-5. PubMed ID: 12015841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
    Strowd RE; Abuali I; Ye X; Lu Y; Grossman SA
    J Neurooncol; 2016 Mar; 127(1):165-71. PubMed ID: 26729269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma.
    Yoda RA; Marxen T; Longo L; Ene C; Wirsching HG; Keene CD; Holland EC; Cimino PJ
    J Neuropathol Exp Neurol; 2019 Nov; 78(11):1002-1010. PubMed ID: 31529048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
    Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
    Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.